Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase I Study to Evaluate the Safety,Tolerability and Preliminary Efficacy of YY001 in Patients with Advanced Solid Tumors

NCT06228846 is registered in ClinicalTrials.gov with Shanghai Yuyao Biotech Co., Ltd. as lead sponsor.

NCT NCT06228846
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06228846 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase I Study to Evaluate the Safety,Tolerability and Preliminary Efficacy of YY001 in Patients with Advanced Solid Tumors
Lead sponsor
Shanghai Yuyao Biotech Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
July 14, 2022
Completion date
May 30, 2024
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor